The U.S. Food and Drug Administration (FDA) granted approval for a generic version of Dapagliflozin (ANDA 211582) on April 6, 2026. This approval allows Zydus Pharmaceuticals to market its generic formulation of the drug, which is known by brand names such as Farxiga and Xigduo XR.
Background
Dapagliflozin is the active pharmaceutical ingredient in several approved medications. It is available as a standalone product (e.g., Farxiga) and in various combination formulations. These combinations include dapagliflozin and metformin hydrochloride (e.g., Xigduo XR) and dapagliflozin and saxagliptin. Other forms mentioned in its aliases include dapagliflozin propanediol and dapagliflozin 2,3-butanediol monohydrate.
What this means
The FDA's approval of a generic version of Dapagliflozin is a significant development for patients and healthcare providers. Generic drugs are bioequivalent to their brand-name counterparts, meaning they work in the same way and provide the same clinical benefit. This approval by the FDA ensures that the generic formulation from Zydus Pharmaceuticals meets the same rigorous standards for quality, strength, purity, and stability as the original brand-name drug. The introduction of generic options typically leads to increased market competition, which can result in lower prices and improved accessibility for patients who rely on Dapagliflozin for their treatment needs. This can be particularly impactful for long-term conditions where medication costs can be a significant barrier to adherence.
Source
The information regarding this approval was sourced from the U.S. Food and Drug Administration (FDA). The approval for Dapagliflozin (ANDA 211582) was recorded on April 6, 2026, and is publicly accessible on the accessdata.fda.gov website.